ClinicalTrials.gg
CompletedNCT03416088Updated Apr 17, 2025

Influence of Daily Activities on Retinal Microcirculation

An interventional study of Beverage consumption and Daily reading in Retinal Microcirculation Disorder, sponsored by Jiannan Huang. Completed at 1 site in China. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-17.

Sponsored by Jiannan Huang · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled May 2017, registered Jan 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The daily behaviors such as drinking coffee, wine, reading, exercise and body postural changes may have influence on the function or morphology of the retinal microcirculation in healthy people.A recent study found that the fingertips microvascular bed constricted obviously after the intake of a cup of coffee with caffeine, it significantly reduced blood flow to the fingers; Long reading of electronic products can induce significant dry eye symptoms, affect visual quality, and cause asthenopia. Microcirculation is critical for regulating vascular resistance and blood flow in organs. Fundus blood vessels is the only visible microvascular in vivo, its morphology and function changes not only associated with eye disease, but also with cardiovascular and cerebrovascular diseases. Optical coherence tomography angiography (OCTA) is a new technique which could acquire blood flow information in a non-invasive way without the use of dye. Magnetic resonance imaging (MRI) can quantitatively evaluation of cerebral blood flow and retina-choroid blood flow using the noninvasive arterial spin labeling technique in a large field of view (FOV) without depth limitations.The study tried to detect the influence of daily behaviors such as drinking coffee, red wine, reading , exercise, etc. on the retinal microcirculation with OCTA and MRI, and provide reference for health behaviors.

02

Conditions studied

  • Retinal Microcirculation Disorder

Keywords

  • Beverage consumption
  • Reading
  • Body motion
  • Retinal microcirculation
  • Optical coherence tomography angiography
  • Magnetic resonance imaging
03

In context

Lead sponsor

Jiannan Huang is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults
  2. The age range was from 18 to 35 years old
  3. Without another eye disease besides ametropia
  4. The spherical equivalent is equal or above minus 3.00 diopters
  5. No smoking or drinking
  6. Average daily caffeine consumption no more than 1 cup of coffee
  7. No diabetes, hypertension, heart disease, liver or kidney dysfunction
  8. No medication taken recently

Exclusion criteria

Exclusion Criteria

  1. Mental disorders such as depression and anxiety
  2. Intellectual disabilities
  3. Female in menstruation, gestation period, perinatal period or lactation period
  4. Unable to cooperate with eye examinations and test procedures
  5. Heart disease, hypertension, diabetes, liver and kidney dysfunction and other chronic diseases
  6. Patients with fever, acute infectious diseases
  7. Other conditions that are not suitable for drinking alcohol or coffee, such as allergic to alcohol or coffee
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Beverage consumption

    Drink 300ml red wine (alcohol concentration:12.5%), 300ml coffee (caffeine concentration 72 mg), 300 ml Baijiu (Chinese liquor, alcohol concentration:12.5%) , SipSparkTM Probiotics (facilitates ethanol degradation) was taken 0.5 hour prior to Baijiu consumption, or 300ml water.

    Behavioral: Beverage consumption

  • Experimental
    Daily reading

    Reading paper books, playing video games with mobile phones, or non-reading.

    Behavioral: Daily reading

  • Experimental
    Body motion

    Exercise and body postural changes.

    Behavioral: Body motion

Interventions

  • BehavioralBeverage consumption

    The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.

  • BehavioralDaily reading

    Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.

  • BehavioralBody motion

    Exercise or body postural changes

06

What researchers measure

Primary outcomes

  1. Vessel diameter index (VDI)

    VDI is calculated using both the vessel area map and the skeletonized vessel map, to yield the averaged vessel caliber.

    Time frame: 3 weeks

  2. Vessel area density (VAD)

    VAD is calculated as a unit-less ratio of the total image area occupied by the vasculature to the total image area in the binary vessel maps.

    Time frame: 3 weeks

  3. Flow impairment region (FIR)

    FIZ: calculated by summing all 'no-flow' pixels up.

    Time frame: 3 weeks

  4. Retina-choroid blood flow

    Blood flow for the entire retinal thickness were determined as a function of the distance from the optic nerve head, where the blood flow was measured at the peaks of the projection profiles. An region of interest outlining the posterior retina with a size of 0.7 to 0.8 mm across the retina-choroid thickness in the parafoveal region was used to obtain the blood flow signal time courses and averaged the values.

    Time frame: 3 weeks

  5. Cerebral blood flow (CBF)

    The frontal lobe was selected as the region of interest (ROI) to measure and average the changes in CBF

    Time frame: 3 weeks

07

Study locations

1 site
  • Shanghai Eye Disease Prevention & Treatment Center
    Shanghai, Shanghai 200040, China
08

References and documents

Publications

  • Malerba S, Turati F, Galeone C, Pelucchi C, Verga F, La Vecchia C, Tavani A. A meta-analysis of prospective studies of coffee consumption and mortality for all causes, cancers and cardiovascular diseases. Eur J Epidemiol. 2013 Jul;28(7):527-39. doi: 10.1007/s10654-013-9834-7. Epub 2013 Aug 11. PubMed 23934579 ↗
  • Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011 Feb 22;342:d671. doi: 10.1136/bmj.d671. PubMed 21343207 ↗
  • Lawrenson JG, Hull CC, Downie LE. The effect of blue-light blocking spectacle lenses on visual performance, macular health and the sleep-wake cycle: a systematic review of the literature. Ophthalmic Physiol Opt. 2017 Nov;37(6):644-654. doi: 10.1111/opo.12406. PubMed 29044670 ↗
  • Karti O, Zengin MO, Kerci SG, Ayhan Z, Kusbeci T. ACUTE EFFECT OF CAFFEINE ON MACULAR MICROCIRCULATION IN HEALTHY SUBJECTS: An Optical Coherence Tomography Angiography Study. Retina. 2019 May;39(5):964-971. doi: 10.1097/IAE.0000000000002058. PubMed 29401177 ↗
  • Luksch A, Resch H, Weigert G, Sacu S, Schmetterer L, Garhofer G. Acute effects of intravenously administered ethanol on retinal vessel diameters and flicker induced vasodilatation in healthy volunteers. Microvasc Res. 2009 Sep;78(2):224-9. doi: 10.1016/j.mvr.2009.06.001. Epub 2009 Jun 10. PubMed 19523476 ↗
  • Strang NM, Claus ED, Ramchandani VA, Graff-Guerrero A, Boileau I, Hendershot CS. Dose-dependent effects of intravenous alcohol administration on cerebral blood flow in young adults. Psychopharmacology (Berl). 2015 Feb;232(4):733-44. doi: 10.1007/s00213-014-3706-z. Epub 2014 Aug 12. PubMed 25110231 ↗
  • Kojima S, Sugiyama T, Kojima M, Azuma I I, Ito S. Effect of the consumption of ethanol on the microcirculation of the human optic nerve head in the acute phase. Jpn J Ophthalmol. 2000 May;44(3):318-9. doi: 10.1016/s0021-5155(00)00158-1. PubMed 10913661 ↗
  • Molnar F, Frank CC. Determining the causes of postural hypotension. Can Fam Physician. 2018 Jan;64(1):40. No abstract available. PubMed 29358250 ↗

Individual participant data

Plan to share: No — No plan to share individual participant data because of personal privacy.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Oct 2020, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2018
First posted
Jan 30, 2018
StartActual
May 1, 2017
Primary completionActual
Oct 31, 2020
CompletionActual
Dec 31, 2020
Last update
Apr 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03416088
Lead sponsor
Jiannan Huang
Responsible party
Jiannan Huang (Director, Shanghai Eye Disease Prevention and Treatment Center) — Sponsor-investigator
First posted
Jan 30, 2018
Start date
May 1, 2017
Primary completion
Oct 31, 2020
Completion
Dec 31, 2020
Last update
Apr 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion